Viral Vector mAKAPβ Fragment to Disrupt PP2A Anchoring in Heart Failure
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for heart failure, such as angiotensin-converting enzyme inhibitors and β-adrenergic receptor blockers, fail to effectively prevent or treat pathological cardiac hypertrophy, which contributes to heart failure progression, particularly in conditions with reduced ejection fraction.
Innovation Solution
Inhibition of the anchoring of protein phosphatase 2A (PP2A) to myomegalin-associated kinase anchoring protein β (mAKAPβ) using a viral-based gene therapy vector encoding a fragment of mAKAPβ to disrupt its interaction with signaling enzymes, thereby modulating hypertrophic pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional treatments such as ACE inhibitors and β-adrenergic receptor blockers are used, then blood pressure control and heart failure management are improved, but pathological cardiac hypertrophy is not effectively prevented or treated
Solution Approach 1:
The patent extracts and targets the specific signaling complex (mAKAPβ-PP2A-RSK3) that mediates pathological hypertrophy, separating this harmful pathway from the general heart failure management approach. By specifically disrupting the mAKAPβ-PP2A interaction, the invention selectively prevents hypertrophic signaling while allowing other compensatory mechanisms to remain intact.
Solution Approach 2:
The patent uses an anchoring disruptor peptide as an intermediary molecule that specifically binds to mAKAPβ and prevents PP2A from anchoring to the complex. This intermediary approach allows selective modulation of the hypertrophic pathway without affecting other signaling pathways, thereby preventing pathological hypertrophy while maintaining heart failure management benefits.
2Object-affected harmful factors
If mAKAPβ-PP2A anchoring is disrupted, then cardiac remodeling is attenuated and hypertrophy is inhibited, but the complexity of the treatment mechanism increases
Solution Approach 1:
The patent employs a peptide-based anchoring disruptor that can be delivered via viral vector, creating a temporary but effective intervention. The peptide itself is a simple, short-lived molecule that transiently disrupts the mAKAPβ-PP2A interaction, providing therapeutic effect without requiring complex long-term structural modifications.
Solution Approach 2:
The patent changes the binding affinity parameter of the mAKAPβ-PP2A interaction by introducing a competing peptide. This parameter change (reducing binding affinity) selectively modulates the hypertrophic pathway activation, allowing control over the signaling complex stability and therapeutic effect duration.
3Reliability
If concentric and eccentric hypertrophy are inhibited, then cardiac function is preserved and survival is improved, but the ability to undergo physiologic adaptation is reduced
Solution Approach 1:
The patent applies partial action by selectively targeting only the pathologic hypertrophic pathway through mAKAPβ-PP2A disruption, while leaving other adaptive pathways intact. This partial inhibition prevents excessive hypertrophy and maintains cardiac function without completely blocking all hypertrophic responses, preserving necessary physiologic adaptability.
Solution Approach 2:
The patent applies local quality by specifically targeting the mAKAPβ-PP2A-RSK3 signaling complex in cardiomyocytes, creating a localized therapeutic effect. This localized approach modulates hypertrophic signaling in specific cells and pathways while preserving other adaptive mechanisms in different tissues or cell types.
Data Source
AI summary
The present invention provides a method of treating heart failure with reduced ejection fraction, by administering to a patient at risk of such damage, a pharmaceutically effective amount of a composition which inhibits the anchoring of PP2A to mAKAPβ. This composition is preferably in the form of a viral based gene therapy vector that encodes a fragment of mAKAPβ to which PP2A binds.